← Back to Screener
Atea Pharmaceuticals, Inc. Common Stock (AVIR)
Price$4.38
Value ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)39.74%
Price vs S&P 500 (4W)-21.28%
VGM Score73.42
Market Capitalization$373.73M
All Metrics
Book Value / Share (Quarterly)$2.92
P/TBV (Annual)0.37x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.85
Price vs S&P 500 (YTD)19.88%
Net Profit Margin (TTM)34.46%
EPS (TTM)$-2.12
10-Day Avg Trading Volume0.33M
EPS Excl Extra (TTM)$-2.12
EPS (Annual)$-2.00
ROI (Annual)-38.28%
Cash / Share (Quarterly)$3.20
ROA (Last FY)-36.15%
EBITD / Share (TTM)$-2.37
ROE (5Y Avg)-13.16%
Operating Margin (TTM)39.41%
Cash Flow / Share (Annual)$-1.69
P/B Ratio1.60x
P/B Ratio (Quarterly)1.83x
Net Income / Employee (Annual)$-3,054,500
EV / Revenue (TTM)0.84x
ROA (TTM)-51.49%
EV / EBITDA (TTM)9.62x
EPS Incl Extra (Annual)$-2.00
Current Ratio (Annual)7.82x
Quick Ratio (Quarterly)7.67x
3-Month Avg Trading Volume0.48M
52-Week Price Return58.31%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.97
P/S Ratio (Annual)1.06x
Asset Turnover (Annual)0.45x
52-Week High$6.45
EPS Excl Extra (Annual)$-2.00
26-Week Price Return55.67%
Quick Ratio (Annual)7.59x
13-Week Price Return-0.21%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.89x
Enterprise Value$294.41M
Asset Turnover (TTM)0.42x
Book Value / Share Growth (5Y)-11.91%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)39.44%
Cash / Share (Annual)$3.86
3-Month Return Std Dev58.41%
Net Income / Employee (TTM)$-3,082,100
ROE (Last FY)-38.28%
EPS Basic Excl Extra (Annual)$-2.00
Receivables Turnover (TTM)85.42x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.12
ROI (TTM)-57.01%
P/S Ratio (TTM)1.06x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.69
Price vs S&P 500 (52W)30.10%
Year-to-Date Return30.81%
5-Day Price Return5.66%
EPS Normalized (Annual)$-2.00
ROA (5Y Avg)-12.39%
Net Profit Margin (Annual)34.49%
Month-to-Date Return-15.24%
Cash Flow / Share (TTM)$-1.57
EBITD / Share (Annual)$-2.29
Operating Margin (Annual)39.39%
ROI (5Y Avg)-13.16%
EPS Basic Excl Extra (TTM)$-2.12
P/TBV (Quarterly)0.41x
P/B Ratio (Annual)1.01x
Pretax Margin (TTM)39.41%
Book Value / Share (Annual)$3.53
Price vs S&P 500 (13W)-9.96%
Beta0.33x
P/FCF (Annual)1.26x
Revenue / Share (TTM)$0.00
ROE (TTM)-57.01%
52-Week Low$2.78
vGradeB
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.57est. -0.60
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AVIRAtea Pharmaceuticals, Inc. Common Stock | B | — | B | $4.38 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing antiviral therapies for serious viral infections. The company's lead candidate, bemnifosbuvir, is in development for COVID-19, and a combination of bemnifosbuvir and ruzasvir is being evaluated for Hepatitis C treatment.